SCOLR Pharma, Inc. Reports Third Quarter 2009 Financi...(2187626 4387636 General and a...),Health

Date:11/6/2009

2,187,626 4,387,636 General and administrative 1,220,745 947,684 3,347,279 3,242,614 --------- ------- --------- --------- 1,847,285 3,371,627 5,735,307 8,175,829 Facility lease termination Gain from lease buyout - (4,100,000) - (4,100,000) Expenses related to relocation and lease buyout - 116,867 - 116,867 --------- ------- --------- --------- Total facility lease buyout - (3,983,133) - (3,983,133) --------- ------- --------- --------- Total operating (revenue) expenses 1,847,285 (611,506) 5,735,307 4,192,696 --------- ------- --------- --------- Income (loss) from operations (1,585,634) 847,814 (5,071,095) (3,411,261) Other income (expense) Interest income 948 45,858 12,060 205,530 Interest expense - (3,393) (3,512) (11,565) Other - 91 - 1,329 --------- ------- --------- --------- Total other income 948 42,556 8,548 195,294 --------- ------- --------- --------- Net income (loss) $(1,584,686) $890,370 $(5,062,547)$(3,215,967) ========= ======== ========= ========= Net income (loss) per share, basic and diluted $(0.04) $.02 $(0.12) $(0.08) ========= ======== ========= ========= Shares used in computing basic net income (lo
'/>"/>

SOURCE SCOLR Pharma, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
4. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
5. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
6. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
7. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
8. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
9. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
10. Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound